Buspirone is a nonbenzodiazepine
anxiolytic that has been effective in uncontrolled trials for treating childhood
anxiety disorders. A 4-year-old boy with a history of
laryngomalacia (congenital structural abnormality with airway collapse and obstruction on inhalation), pharyngeal
dysphagia (difficulty in swallowing), poor
weight gain, delayed self-feeding skills, and anxiety symptoms is described. An open trial of
buspirone, increased gradually to 12.5 mg daily in divided doses over a period of 22 weeks, was associated with decreased anxiety, improved self-feeding skills, and
weight gain. Based on parental reports,
buspirone appeared to decrease separation and social anxiety, as well as anxiety associated with eating.
Drug discontinuation was associated with symptom relapse, whereas
drug readministration lead to the same clinical benefits that had been observed previously. The medication was well tolerated, and its benefits have persisted for over 1 year. No new recommendations can be made regarding the use of
buspirone in preschool children or in the treatment of anxious behaviors adversely affecting medical conditions in children and adolescents.